ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

ImClone “Screwed Up,” CEO Waksal Tells Conference; Stock Plunges.

January 11, 2002

Bailer NEJM “Irresponsible, Purposely Misleading,” Ignored Facts, DeVita Tells NCA

May 23, 1986

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011

Survival After Liver Transplant Called Excellent In Study

November 28, 2003

In Brief: No Decision Yet On How CALB Cuts Will Be Made; Wyngaarden Of Duke Will Be New Director of NIH

January 29, 1982

Biomarker Test Outperforms PSA and Gleason Score in Study

July 26, 2013